Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens

ClinicalTrials.gov ID: NCT01721759

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01721759. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Single-Arm Phase 2 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study is to assess the objective response rate (change in tumor size from baseline) in patients with advanced or metastatic squamous cell nonsmall-cell lung cancer treated with Nivolumab (BMS-936558) after failure of 2 prior systemic regimens

Study identification

NCT ID
NCT01721759
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
117 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 16, 2012 (Actual)
Primary completion
Jan 22, 2014 (Actual)
Completion
Apr 22, 2021 (Actual)
Last update posted
Jun 28, 2022

2012 – 2021

United States locations

U.S. sites
20
U.S. states
14
U.S. cities
18
Facility City State ZIP Site status
University Of California Davis Medical Center Sacramento California 95817 —
Va San Diego Healthcare System San Diego California 92161 —
H. Lee Moffitt Cancer Center & Research Institute Tampa Florida 33612 —
Winship Cancer Institute. Atlanta Georgia 30322 —
Local Institution Metairie Louisiana 70006 —
Tufts Medical Center Boston Massachusetts 02111 —
Providence Cancer Institute Southfield Michigan 48075 —
Mayo Clinic Rochester Minnesota 55905 —
Roswell Park Cancer Institute Buffalo New York 14263 —
Beth Israel Comprehensive Cancer Center New York New York 10011 —
Memorial Sloan-Kettering Cancer Center New York New York 10065 —
University Of North Carolina At Chapel Hill Chapel Hill North Carolina 27599-7305 —
University Hospitals Cleveland Medical Center Cleveland Ohio 44106 —
The Ohio State University Columbus Ohio 43210 —
Providence Oncology And Hematology Portland Oregon 97213 —
Oregon Health & Science University Portland Oregon 97239 —
Network Office of Research and Innovation Allentown Pennsylvania 18103 —
University Of Pittsburgh Medical Center Pittsburgh Pennsylvania 15232 —
Henry-Joyce Cancer Center Nashville Tennessee 37232 —
Oncology Consultants, Pa Houston Texas 77024 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01721759, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 28, 2022 · Synced Nov 15, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.